MedTrace Logo

Cardiovascular-kidney-metabolic (CKM)-Guided Therapy for Patients After Acute Coronary Syndrome

NCT07773272 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1215

Last updated 2026-08-19

No results posted yet for this study

Summary

Patients with a history of myocardial infarction are at significantly increased risk of recurrent cardiovascular events. Despite established clinical guidelines, secondary preventive care is often initiated too late, inadequate in intensity or incomplete in application. As a result, important opportunities to prevent serious outcomes are missed.

The aim of this project is to investigate whether rapid, guideline-based treatment following myocardial infarction leads to improved patient outcomes. The study protocol is based on current clinical guidelines and targets key domains including diabetes, hypertension, and hypercholesterolemia. Outcomes of patients treated according to the study protocol will be compared to those receiving standard care. Primary endpoints include major adverse cardiac- and cerebrovascular events within a 24-month follow-up period.

The investigators hypothesize that rapid, guideline-based intervention will result in improved risk factor management, leading to a reduction in cardiovascular events and mortality. For patients, this may translate into improved health, quality of life and life expectancy. This project aims to deliver a practical protocol for effective secondary prevention in clinical practice, which is expected to reduce healthcare utilization in the long term. With this initiative, the investigators seek to take a significant step toward improving post-myocardial infarction care and contributing to sustainable cardiovascular healthcare.

Conditions

  • Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
  • Hypercholerolemia
  • Hypertension
  • Diabete Mellitus
  • Cardiovascular Risk Management

Interventions

DRUG

Rapid ESC-guideline based secondary prevention following myocardial infaction

In the intervention group, patients will be treated according to a rapid ESC-guideline-based protocol. This approach will target: 1\. Optimal pharmacological treatment, including: * Lipid-lowering * Antihypertensive * Diabetic, such sodium-glucose co-transporter 2 inhibitors (SGLT-2 inhibitors) * Glucagon-like peptide-1 agonists (GLP-1 agonists)

Sponsors & Collaborators

  • Zuyderland Medisch Centrum

    lead OTHER

Principal Investigators

  • Saman Rasoul, MD, PhD · Zuyderland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-16
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07773272 on ClinicalTrials.gov